Norgine, Axa and Debiopharm are in line for exits as the breast cancer diagnostics test provider is aiming to go public to boost research and development and commercial activities.

Agendia, a Netherlands-headquartered breast cancer diagnostics technology provider that counts insurance company Axa and pharmaceutical firms Debiopharm and Norgine as backers, filed for an initial public offering on the Nasdaq Global Market on Thursday.

Founded in 2003, Agendia developed two diagnostics systems, MammaPrint and Blueprint, designed respectively to assess the risk of a patient’s cancer recurring and to understand the underlying genetic reasons behind the growth of a tumour.

The company has filed to raise up to $75m and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn